The use of contralateral prophylactic mastectomies (CPMs) among patients with invasive unilateral breast cancer has increased substantially during the past decade in the United States despite the lack of evidence for survival benefit. However, whether this trend varies by state or whether it is correlated with changes in proportions of reconstructive surgery among these patients is unclear.
B reast cancer is the most commonly diagnosed cancer and the second leading cause of cancer death among women in the United States. 1 Treatment for breast cancer varies by hormone and human epidermal growth factor receptor 2 status, stage, and histologic type and may include a combination of surgery, chemotherapy, hormonal therapy, and radiotherapy. Several studies in the United States have reported a marked increase in the use of contralateral prophylactic mastectomies (CPMs) for women who receive a diagnosis of earlystage unilateral breast cancer, particularly for patients younger than 45 years of age, 2-4 despite a lack of evidence for survival benefit. [5] [6] [7] [8] [9] The reasons for this increasing pattern are unclear but are thought to include the fear of developing a second breast cancer and the desire for breast symmetry following reconstructive surgery.
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Two previous studies based on the Surveillance, Epidemiology, and End Results (SEER) database 13 and the National Cancer Data Base (NCDB) 2 reported regional variation in the proportions of CPMs. However, these studies were limited because the SEER database (a population-based cancer registry) covers only 28% of the US population 14 and because the NCDB (a hospital-based cancer registry) coverage in some states (eg, 27% in Arizona) is too low to provide representative statespecific estimates.
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We examined temporal trends by state and age in the proportion of patients who received CPMs among women diagnosed with invasive unilateral early-stage breast cancer and treated with surgery from 2004 through 2012. We used nationwide population-based incidence data as collected by the SEER program and the National Program of Cancer Registries and compiled by the North American Association of Central Cancer Registries (NAACCR). 17 Using these data, we also examined whether the temporal changes in the proportion of women receiving a CPM by state were correlated with changes in the proportion of women undergoing reconstructive surgery following a CPM.
Methods

Data Source and Variables
Demographic and clinical information for women 20 years of age or older who received a diagnosis of primary invasive unilateral breast cancer between January 1, 2004, and December 31, 2012 (n = 1 404 411), was obtained from the NAACCR database for the District of Columbia and all states except for the nonconsenting states of Illinois, Maryland, and Vermont and owing to a lack of readily available data in Kansas and Minnesota. This project was reviewed and approved by the NAACCR institutional review board and was exempt from informed consent of individual study participants because it used only deidentified patient data. Surgical interventions were categorized as breast-conserving surgery (BCS), unilateral mastectomy (UM) with or without reconstruction, or CPM with or without reconstruction. Stage Tumor size was grouped into 3 categories: less than 2 cm, 2 to 4.9 cm, and 5 to 20 cm; cases with a likely erroneously recorded tumor size of more than 20 cm (n = 1262) were classified as missing tumor size. Tumor grade was categorized as well differentiated, moderately differentiated, poorly differentiated, or undifferentiated. Race/ethnicity was categorized as non-Hispanic white, non-Hispanic black, non-Hispanic other, and Hispanic based on self-identified race and Hispanic origin. 19 Age at diagnosis was categorized in 10-year age groups to compare CPMs with other surgical procedures at the national level. To investigate CPM trends temporally and geographically, age at diagnosis was collapsed into 2 categories: 20 to 44 years of age and 45 years of age or older, with a particular emphasis on women 20 to 44 years of age, for whom a CPM is more common.
Statistical Analysis
Statistical analysis was performed from August 1, 2015, to August 31, 2016. For each state, we calculated the proportion of patients undergoing a CPM among all women with early-stage unilateral breast cancer treated with surgery (BCS, UM, or CPM) by age (20-44 vs ≥45 years) and year of diagnosis averaged across 3 years (2004-2006, 2007-2009, and 2010-2012) . We aggregated data across 3 years so that all state-specific estimates were based on at least 10 cases. Temporal trends in the proportion of patients undergoing a CPM between the first (2004) (2005) (2006) and last (2010-2012) 3-year period were calculated as a prevalence ratio (PR) with asymptotic 95% CIs. 20 To illustrate variation by state, maps of the United States were created in ArcMap, version 10.3.1 (ESRI).
To show changes in the temporal trend over time for each of the 2 age groups (20-44 and ≥45 years), we used a joinpoint model, with a maximum of 1 joinpoint allowed. A log-transformed model was used to approximate a fixed annual percent change (APC) to account for the skewed distribution over time. In this method, the APC is calculated by fitting a least-squares regression line to the natural logarithm of the proportion, using year of diagnosis as the regressor variable. 21 In the presence of a significant joinpoint, 2 values for APC were calculated, preceding and following the identified joinpoint.
Key Points
Question Does the proportion of contralateral prophylactic mastectomies vary by state?
Findings In this cohort study of more than 1.2 million women who received a diagnosis of invasive unilateral early-stage breast cancer treated with surgery, the proportion of contralateral prophylactic mastectomies varied substantially by state. The proportion among women 20 to 44 years of age during the period from 2010 to 2012 ranged from 15.7% in Hawaii to 42.8% to 48.5% in 5 contiguous Midwestern states.
Meaning Patients should be educated about the benefit and harm of a contralateral prophylactic mastectomy for informed decision making.
Multivariable analysis was conducted using binary logistic regression, in which the outcome variable was CPM vs other surgery (UM or BCS). A second logistic regression model was fitted restricted only to patients who underwent a mastectomy (CPM vs UM). For both of these analyses, a single model was fit to the data, and the results were reported as odds ratios adjusted for the effect of the other covariates and 95% CIs. Statistical analyses were performed using SAS, version 9.4 (SAS Institute Inc), and joinpoint analysis was performed using Joinpoint Regression Program, version 4.2.0.2 (NCI). P = .05 (2-tailed) was considered significant.
We also examined state-specific trends in reconstructive surgery by age (20-44 years and ≥45 years) and year of diagnosis for women who underwent a CPM or a UM. We correlated the proportion of CPMs among women 20 to 44 years of age with early-stage unilateral breast cancer treated with surgery during the most recent period (2010-2012) with the proportion of reconstructive surgical procedures among women who were diagnosed with early-stage breast cancer and received a CPM by state, as well as the relative percent change in the proportion of CPMs among women with early-stage unilateral breast cancer treated with surgery between 2004-2006 and 2010-2012 with the corresponding relative percent change in reconstructive surgery, using the Pearson correlation coefficient. We repeated these correlation analyses with proportions of reconstructive surgical procedures among women who were diagnosed with early-stage breast cancer and received a mastectomy (either a UM or a CPM).
Results
Of 1 224 947 patients with unilateral early-stage breast cancer who underwent surgery between 2004 and 2012 and met the inclusion criteria, 715 914 (58.4%) had BCS, 402 434 (32.9%) had a UM, and 106 599 (8.7%) had a CPM (Table 1) . Nationally, the proportion of patients undergoing a CPM monotonically increased with younger age from 2.4% (7891 of 330 Multivariable analysis also showed that the odds of undergoing a CPM compared with other surgery (BCS or UM) were significantly higher for younger patients (eTable 1 in the Supplement). In binary logistic regression, the odds of undergoing a CPM compared with other surgery ranged from 2.5 (95% CI, 2.5-2.6) for patients 60 to 69 years of age to 18.6 (95% CI, 17.4-19.8) for patients 20 to 29 years of age compared with patients 70 years of age or older. In addition, the odds of undergoing a CPM compared with other surgical procedures were significantly higher for patients who received a diagnosis of node-positive regional stage disease than for patients who received a diagnosis of local stage disease and were higher for patients with lobular carcinoma than for patients with ductal carcinoma, as well as for white vs nonwhite patients and for privately insured vs uninsured or non-privately insured patients. In contrast, in analyses restricted to patients receiving a mastectomy, the odds of undergoing a CPM compared with a UM were lower for patients who received a diagnosis of regional stage disease than for patients who received a diagnosis of local stage disease and were lower for patients with large tumors (≥2 cm) than for patients with small tumors (<2 cm) (eTable 1 in the Supplement). The proportions of CPMs among women 20 to 44 years of age with early-stage unilateral breast cancer treated with surgery by state and year of diagnosis are presented in Virginia, and Utah (eTable 3 in the Supplement). Likewise, the proportion of CPMs among women 45 years or older with earlystage unilateral breast cancer treated with surgery substantially varied across states in each time period. For example, during the period from 2010 to 2012, the proportions of patients who underwent a CPM ranged from less than 5% in Massachusetts, Hawaii, and Rhode Island to more than 16% in Colorado (eTable 3 in the Supplement). In general, the highest proportions of women 45 years of age or older who underwent a CPM were observed in select Southern and Midwestern states, and the lowest proportions were found in Northeast and Western states (Figure 2 ). Abbreviations: L, localized; RE, regional by direct extension only; RE+RN, regional by both direct extension and lymph node involvement; RN, regional by lymph node involvement. The proportion of reconstructive surgical procedures also increased among patients who received a UM during the study period in most states. During the most recent time period (2010-2012), the proportion of reconstructive surgical procedures among women 20 to 44 years of age receiving a UM ranged from less than 20% in Washington, Oklahoma, New Mexico, and Hawaii to 66% in Massachusetts (eTable 7 in the Supplement). Among women 45 years of age or older receiving a UM, the proportion of reconstructive surgical procedrues ranged from about 7% in Alaska 
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Discussion
Using a nationwide population-based cancer database, we found that the proportion of CPMs among patients 20 years or older with early-stage unilateral breast cancer treated with surgery significantly increased from 2004 to 2012 in almost all states, with the absolute proportions substantially higher among patients 20 to 44 years of age than among those 45 years of age or older and in some Midwestern and Southern states than in Western and Northeastern states. In 5 contiguous Midwestern states (South Dakota, Colorado, Nebraska, Iowa, and Missouri), nearly half of the young women who underwent surgery for early-stage unilateral breast cancer during the period from 2010 to 2012 underwent a CPM.
Factors associated with receipt of a CPM that may contribute to variations by state in the proportion of women who underwent a CPM include regional differences in distribution of white race, high socioeconomic status, testing for high-risk genetic mutations, reconstructive surgery for breast symmetry, use of magnetic resonance imaging (MRI), and fear and anxiety surrounding a diagnosis of breast cancer.
12,22-27 However, we found no association between the temporal increases in It has been suggested that regional differences in the use of elective surgical procedures largely reflect geographical differences in physician practice, beliefs, and financial incentives rather than differences in patient factors. showed that proportions of CPMs were highest in teaching 
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Regional Variation in Contralateral Prophylactic Mastectomy in the United States hospitals and lowest in community hospitals, suggesting
Limitations
To our knowledge, our study is the first to show state-level variation based on population-based data and highlights a contiguous region of states that have substantially higher-thanaverage proportions of CPMs among women with early-stage unilateral breast cancer treated with surgery. However, a no- ; however, our study lacked data on these variables. Also lacking in our analytical database were important clinical indicators affecting surgical decisions, such as mammographic patterns of diffuse microcalcifications, presence of multiple tumors, and failed lumpectomy attempts.
Studies examining decision aids have suggested that a mastectomy is less likely for early-stage breast cancer among women who are fully informed about surgical options. 
Conclusions
Using a nationwide population-based database, we found substantial geographical variation in the receipt of a CPM among US women with unilateral breast cancer treated with surgery, with nearly 1 in 2 patients 20 to 44 years of age during the period from 2010 to 2012 receiving a CPM in 5 contiguous Midwestern states. This regional variation was partly explained by state variations in reconstructive surgical procedures among all women with a mastectomy but not among women who underwent a CPM. Future studies should examine patient-level, clinician-level, and health system-level factors to provide additional insight into the reasons for temporal changes and regional variation in the receipt of a CPM. In the meantime, however, surgeons and other health care professionals should educate their patients about the benefit, harm, and cost of a CPM to help patients make informed decisions about their treatments.
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Accepted for Publication: January 8, 2017. Choices regarding breast cancer surgery-much like casting a ballot-can be intensely personal decisions, based on one's lifetime experiences and exposures, as well as values and resources. Patients and voters alike deserve accurate information regarding realistic expectations from their options. The responsible journalist strives to protect the public from hollow promises by politicians that are all too easily made in the heat of election campaigns. It is an ethical and moral imperative for the responsible surgeon to insure that patients with breast cancer are well informed regarding treatment choices that are medically safe and that prioritize optimal oncologic outcomes. We must respect patient choice and avoid being paternalistic, but we must also protect our patients from making impulsive surgical decisions when they are freshly encumbered by the panic accompanying a new diagnosis of breast cancer. 
